CN112402554A - Traditional Chinese medicine composition for treating leukoencephalopathy and application thereof - Google Patents

Traditional Chinese medicine composition for treating leukoencephalopathy and application thereof Download PDF

Info

Publication number
CN112402554A
CN112402554A CN202011153269.5A CN202011153269A CN112402554A CN 112402554 A CN112402554 A CN 112402554A CN 202011153269 A CN202011153269 A CN 202011153269A CN 112402554 A CN112402554 A CN 112402554A
Authority
CN
China
Prior art keywords
parts
traditional chinese
chinese medicine
medicine composition
leukoencephalopathy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202011153269.5A
Other languages
Chinese (zh)
Other versions
CN112402554B (en
Inventor
黄世敬
潘菊华
张颖
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guanganmen Hospital of CACMS
Original Assignee
Guanganmen Hospital of CACMS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guanganmen Hospital of CACMS filed Critical Guanganmen Hospital of CACMS
Priority to CN202011153269.5A priority Critical patent/CN112402554B/en
Publication of CN112402554A publication Critical patent/CN112402554A/en
Application granted granted Critical
Publication of CN112402554B publication Critical patent/CN112402554B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/896Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8969Polygonatum (Solomon's seal)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37Digestive system
    • A61K35/413Gall bladder; Bile
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06Fungi, e.g. yeasts
    • A61K36/07Basidiomycota, e.g. Cryptococcus
    • A61K36/076Poria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/23Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/233Bupleurum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/488Pueraria (kudzu)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537Salvia (sage)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/65Paeoniaceae (Peony family), e.g. Chinese peony
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/69Polygalaceae (Milkwort family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/71Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/72Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
    • A61K36/725Ziziphus, e.g. jujube
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/74Rubiaceae (Madder family)
    • A61K36/746Morinda
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/898Orchidaceae (Orchid family)
    • A61K36/8988Gastrodia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/906Zingiberaceae (Ginger family)
    • A61K36/9062Alpinia, e.g. red ginger or galangal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention discloses a traditional Chinese medicine composition for treating leukoencephalopathy and application thereof, wherein the traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 8-30 parts of wine sealwort, 10-50 parts of kudzu root, 10-30 parts of tuckahoe, 6-15 parts of prepared polygala root and 0.2-1.0 part of artificial bezoar. The invention also discloses application of the traditional Chinese medicine composition in preparing a medicine for treating the leukoencephalopathy. The traditional Chinese medicine composition aims at tonifying kidney and spleen, reducing phlegm and activating blood, detoxifying and dredging collaterals, treating ischemic cerebral white disease, and effectively improving cognitive hypofunction, depression, dizziness, insomnia and the like caused by the ischemic cerebral white disease.

Description

Traditional Chinese medicine composition for treating leukoencephalopathy and application thereof
Technical Field
The invention relates to the technical field of traditional Chinese medicine. More particularly, relates to a traditional Chinese medicine composition for treating leukoencephalopathy and application thereof.
Background
Ischemic leukoencephalopathy is the damage of myelin sheath of central nerve cells in white brain matter caused by chronic cerebral blood supply insufficiency, and the clinical manifestations of ischemic leukoencephalopathy are mainly emotional and cognitive disorders, such as anxiety, depression, cognitive hypofunction and even dementia. It is generally considered that white brain lesions (WML), Leukoencephalopathy (LA), Mild Cognitive Impairment (MCI), Vascular Dementia (VD), Vascular Depression (VD), and cerebrovascular Small Vessel Disease (SVD) belong to the category related to the disease. The disease is mostly developed in middle-aged and elderly people, the incidence rate of the disease is in an increasing trend along with the increase of age, and researches show that about 25 percent of individuals in the elderly people with the age of more than or equal to 65 years have different degrees of white matter change. Early clinical symptoms of the disease are more hidden and atypical and are easy to ignore, so that early detection and intervention are particularly important for treating the disease.
At present, the pathogenesis of the disease is not completely clear, no clear treatment method exists in western medicine, and the western medicine mainly starts from the aspects of changing living habits, controlling risk factors of the cerebrovascular disease, applying medicaments for improving the affective disorder such as a cholinesterase inhibitor, a 5-hydroxytryptamine reuptake inhibitor and the like. The research reports of Chinese medical researchers on the etiology and pathogenesis of the disease, the treatment principle and the Chinese medical treatment are many, most of the Chinese medical researchers advocate that whether the traditional Chinese medicine can improve the common clinical symptoms caused by the ischemic leukoencephalopathy, such as cognitive dysfunction, depression and the like, are taken as research contents, various related scoring scales are taken as the judgment standard for improving the symptoms, or whether various indexes related to hemorheology and the like can be reduced are taken as the standard for treating the disease to be effective, and the research reports on the aspects of whether various Chinese medical treatment modes can improve the microscopic pathological structure of the leukoencephalopathy are few.
Therefore, new judgment standards need to be introduced so as to screen out more effective traditional Chinese medicines for treating the leukoencephalopathy.
Disclosure of Invention
One object of the present invention is to provide a novel Chinese medicinal composition for effectively treating leukoencephalopathy. In addition, the traditional Chinese medicine composition can also be used for treating common clinical symptoms accompanied by most of patients with the leukoencephalopathy, such as dizziness, insomnia, amnesia, depression and the like, and has obvious treatment and improvement effects.
The invention also aims to provide application of the traditional Chinese medicine composition.
In order to achieve the purpose, the invention adopts the following technical scheme:
the invention provides a traditional Chinese medicine composition for treating leukoencephalopathy, which is prepared from the following raw material medicines in parts by weight: 8-30 parts of wine sealwort, 10-50 parts of kudzu root, 10-30 parts of tuckahoe, 6-15 parts of prepared polygala root and 0.2-1.0 part of artificial bezoar.
In the invention, the polygonatum kingianum and the kudzuvine root are monarch drugs. Rhizoma Polygonati is sweet in taste and neutral in nature, and has effects of invigorating qi, nourishing yin, invigorating spleen, invigorating kidney, nourishing congenital foundation, replenishing marrow, and nourishing brain; the kudzu root is sweet and pungent in flavor, cool in nature, enters lung and stomach meridians, has the property of dispersing and ascending, is guided upwards to open the xuanfu to dredge the meridians and collaterals; rhizoma Polygonati and radix Puerariae are combined to supplement and purge, and supplement qi and nourish yin, and dredge meridians and promote blood circulation, so as to supplement primordial qi without stagnation.
Poria and cortex et radix Polygalae can be used as ministerial drugs. The tuckahoe has sweet and light taste and neutral nature, and has the functions of tonifying spleen and qi, promoting diuresis with light excretion and calming heart and tranquilizing the mind, and the tuckahoe enters heart, spleen and kidney channels; the polygala root is pungent, bitter and warm, enters heart, kidney and lung channels, and has the effects of soothing nerves, benefiting intelligence, eliminating phlegm and resolving depression; the two medicines are used together to play the effects of excreting dampness and resolving phlegm, and soothing the nerves and benefiting intelligence.
The artificial bezoar, sweet in taste and cool in nature, enters heart and liver meridians, is an adjuvant and guiding drug: to introduce meridian herbs, the herbs are introduced into the brain to open the chest of brain. Has the effects of clearing away heat and toxic materials, eliminating phlegm and arresting convulsion, and relieving heat toxin and turbid phlegm. The five medicines are combined to play the roles of tonifying the kidney, benefiting the brain, reducing phlegm and activating blood circulation.
The raw materials of the traditional Chinese medicine composition form a basic recipe, and in a specific embodiment of the invention, the traditional Chinese medicine composition can be adjusted on the basis of clinical symptoms, and the traditional Chinese medicine composition comprises the following raw materials in parts by weight:
(1) 10-30 parts of gastrodia elata is added for patients with obvious dizziness. Gastrodia elata is sweet in taste and neutral in nature; the essential herbs entering liver meridian and stopping dizziness can calm down internal wind, dispel external wind, calm down liver yang and dredge meridians. It is combined with Ge Gen to strengthen its actions of dispelling wind and dredging meridians.
(2) For insomnia, 10-30 parts of salvia miltiorrhiza and 10-60 parts of spina date seed are combined. The salvia miltiorrhiza, bitter and slightly cold, which belongs to heart and liver channels, can activate blood and cool blood, remove stasis and dredge channels, relieve restlessness and tranquilize mind, smooth blood vessels and ensure that blood circulation is not stagnated; spina date seed, sour and sweet in taste, enters liver, gallbladder and heart channels, and can nourish heart, tonify liver, calm heart, calm nerves, arrest sweating and promote the production of body fluid; the combination of the two medicines can enhance the effect of soothing the nerves of the tuckahoe and the polygala root, and play the effect of calming the heart and soothing the nerves together, so that the effects of promoting blood circulation and cooling blood and nourishing blood and yin complement each other.
(3) For patients with obvious amnesia, 6-15 parts of fructus Alpinae Oxyphyllae are added. Yi Zhi ren, pungent and warm in property, enters spleen and kidney meridians, can warm and tonify kidney yang, fill marrow and nourish brain, benefit intelligence, and warm and tonify spleen yang. It is combined with Jiu Huang Jing and Yuan Zhi to reinforce its actions of tonifying kidney, tranquilizing mind and improving intelligence.
(4) For patients with obvious depression, 6-15 parts of radix bupleuri, 6-20 parts of red paeony root and 6-20 parts of morinda officinalis are added. Bupleuri radix is pungent and bitter in flavor and slightly cold in nature, enters liver, gallbladder and lung meridians, and can soothe liver, relieve depression, and harmonize exterior and interior. Radix Paeoniae Rubra is bitter in taste and slightly cold in nature, enters liver meridian, clears heat and cools blood, disperses stagnant heat in blood, and radix bupleuri is combined with radix Paeoniae Rubra to regulate qi and activate blood, so as to regulate qi and blood and relieve stasis.
The adjustment mode can select any one or combination of a plurality of symptoms according to different symptoms, so as to achieve the purposes of treating the leukoencephalopathy and improving some combined chronic common diseases, further enhance the adaptability of the composition and improve the treatment effect.
When in use, the Chinese medicinal composition can be prepared into decoction according to the traditional preparation method of the prescription, for example, the decoction is taken after being decocted with water. Or refining the effective components of the preparation with water or other suitable solvent, and making into various preparations such as granule, pill, capsule, tablet, powder, oral liquid, etc. by conventional preparation process. Experiments prove that the preparation method and the use method can realize the treatment effect of the medicine.
The invention also provides application of the traditional Chinese medicine composition in preparing a medicine for treating the leukoencephalopathy.
In addition, unless otherwise specified, all the raw material drugs of the Chinese medicinal composition can be commercially available, and the Chinese medicinal composition in any range including any value between the endpoints and any sub-range composed of any value between the endpoints or any value between the endpoints can achieve the purpose of treating the leukoencephalopathy.
The invention has the following beneficial effects:
the traditional Chinese medicine composition aims at tonifying kidney and spleen, reducing phlegm and activating blood, detoxifying and dredging collaterals, treating ischemic cerebral white disease, and effectively improving cognitive hypofunction, depression, dizziness, insomnia and the like caused by the ischemic cerebral white disease.
Drawings
The following describes embodiments of the present invention in further detail with reference to the accompanying drawings.
FIG. 1 shows HE staining showing pathological morphological changes (× 200) in rat callus; the traditional Chinese medicine composition comprises a pseudo-operation group, a model group and the traditional Chinese medicine composition.
FIG. 2 shows myelin staining showing pathological morphological changes in rat corpus callosum (. times.200); the traditional Chinese medicine composition comprises a pseudo-operation group, a model group and the traditional Chinese medicine composition.
FIG. 3 shows callus MBP immunohistochemistry (× 200); the traditional Chinese medicine composition comprises a pseudo-operation group, a model group and the traditional Chinese medicine composition.
Figure 4 shows HE staining showing pathological morphological changes in rat hippocampus (x 400); the traditional Chinese medicine composition comprises a pseudo-operation group, a model group and the traditional Chinese medicine composition.
Detailed Description
In order to more clearly illustrate the invention, the invention is further described below with reference to preferred embodiments and the accompanying drawings. Similar parts in the figures are denoted by the same reference numerals. It is to be understood by persons skilled in the art that the following detailed description is illustrative and not restrictive, and is not to be taken as limiting the scope of the invention.
Example 1A Chinese medicinal composition for treating leukoencephalopathy (Polygonatum brain tonic formulation)
A traditional Chinese medicine composition for treating leukoencephalopathy is prepared from the following raw material medicines: 8 parts of wine sealwort, 10 parts of kudzu root, 10 parts of tuckahoe, 6 parts of prepared polygala root and 0.2 part of artificial bezoar.
Example 2A Chinese medicinal composition for treating leukoencephalopathy (Polygonatum brain tonic formulation)
A traditional Chinese medicine composition for treating leukoencephalopathy is prepared from the following raw material medicines: 30 parts of rhizoma polygonati preparata, 50 parts of radix puerariae, 30 parts of poria cocos, 15 parts of prepared polygala tenuifolia and 1 part of calculus bovis factitius.
Example 3A Chinese medicinal composition for treating leukoencephalopathy (Polygonatum brain tonic formulation)
A traditional Chinese medicine composition for treating leukoencephalopathy is prepared from the following raw material medicines: 15 parts of wine sealwort, 15 parts of kudzu root, 15 parts of tuckahoe, 10 parts of prepared polygala root and 0.25 part of artificial bezoar.
Example 4 Effect of the Chinese medicinal composition of the present invention on the action of the rats in the model of ischemic leukoencephalopathy for the intervention of behaviourology and cerebral blood flow changes
1 Material
1.1 Experimental animals
Selection of adult Male SD rats
1.2 Experimental drugs
Example 3 the Chinese medicinal composition
2 method
2.1 animal models
The experimental model establishing method comprises the following steps: a bilateral common carotid artery permanent Ligation (LBCCA) method is adopted for the rats to establish a rat model with the ischemic cerebral leukosis.
2.1.1 permanent bilateral common carotid Ligation (LBCCA)
After the rats are bred in the adaptive environment, marking, weighing and randomly dividing the rats into a sham operation group and an operation group. All rats were fasted 12 hours before LBCCA without water deprivation. After the surgery was started, rats were anesthetized with 10% chloral hydrate (350mg/kg) in the abdominal cavity, fixed in the supine position with a mouse plate, sterilized with iodophor at the front of the neck, and depilated for skin preparation. Cutting a 1.5-2.0cm incision along the middle of the neck of a rat longitudinally, separating tissues such as muscles, fascia and the like bluntly by using a hemostatic forceps, searching a common carotid artery from one side, paying attention to the separation of vagus nerves tightly attached to the artery, then respectively ligating the proximal end and the distal end of the common carotid artery by using a No. 5 silk thread, and slightly cutting the common carotid artery by using a surgical scissors with the interval of about 1cm in the middle. The ligation of the contralateral side is carried out at an interval of 30 minutes, and the wound is covered by physiological saline infiltrated with sterile gauze in the gap. After the bilateral common carotid arteries are ligated, the skin penicillin sodium aqueous solution (20 ten thousand/body) is sutured by a No. 0 silk thread and is injected in the abdominal cavity to prevent wound infection. After operation, the rat is placed on a constant temperature pad at 37 ℃ for heat preservation and air circulation is kept, and the rat is returned to the rat cage after reviving and is normally raised. 3 days after the operation, the injection of penicillin sodium aqueous solution subcutaneously every day can prevent infection. When the rats are treated in the sham operation group, the rats are only threaded without ligation and do not cut off the common carotid artery, and the other steps are the same as the operation group.
2.2 animal groups
Comprises a pseudo-operation group, a traditional Chinese medicine group and a model group.
2.3 methods of drug intervention
2.3.1 method of drug compounding
The total amount of medicinal decoction pieces (except artificial bezoar) prepared according to the compatibility proportion of the embodiment 3 is 1890g, and after being soaked in distilled water for 30 minutes, the mixture is placed in a stainless steel decocting pot and heated by an electromagnetic oven. The ratio of distilled water to the medicine is 8L/kg. After boiling with strong fire, decocting with slow fire for 30 minutes. Then filtering out the liquid medicine, adding distilled water, decocting for the second time, adding water and the medicine at the ratio of 6L/kg, boiling with strong fire, and decocting with slow fire for 30 minutes. Collecting the first decoction and the second decoction, decocting in stainless steel decocting pan, concentrating, transferring to evaporating dish for further concentration when the medicinal liquid is concentrated to viscous state, concentrating to 1750ml, and storing for use, wherein the crude drug concentration is about 1.08 g/ml. The artificial bezoar is dissolved into the liquid medicine according to the proportion before the rat is perfused with the stomach.
The gavage amount of the rats in the traditional Chinese medicine group is 6 times of the daily dosage of an adult as an equivalent dosage (the weight of a normal adult is converted into 60 kg), and the prepared medicine is administered.
2.3.2 methods of administration
Each treatment group started gavage administration on the 9 th day of the model creation, and the sham operation group and the model group were given distilled water of the same volume to achieve the purpose of similar stimulation. The gavage dose was adjusted weekly for 42 days according to the change in body weight.
2.4 behavioural Observation methods
2.4.1 sweet Water preference test
2.4.2 Water maze experiment
2.5 cerebral blood flow measurement
2.6 statistical methods
After the data used is recorded into a computer, statistical analysis is performed by using SPSS22.0 statistical software. The method comprises the steps of firstly carrying out normality test and homogeneity of variance test on data, adopting One-way ANOVA (One-way ANOVA) if the data are subjected to normal distribution, comparing every two data by adopting t test or LSD, and adopting Tamhane's T2 if variance is irregular. The test standards are all 0.05, and the statistical data are expressed as mean value plus or minus standard deviation
Figure BDA0002741874180000065
Figure BDA0002741874180000066
And (4) showing.
3 results
3.1
3.2 results of behavioral experiments
3.2.1 results of sugar Water preference experiments
After the traditional Chinese medicine intervention is finished, the percentage of sugar water consumption of each group has no obvious difference (P is more than 0.05).
3.2.2 Water maze test results
1) Water maze positioning navigation experimental result
TABLE 1 Water maze positioning navigation experiment results (
Figure BDA0002741874180000061
n=8)
Figure BDA0002741874180000062
Note:P<0.05,△△P<0.01 compared to the sham group*P<0.05,**P<0.01 comparison with model set
As shown in Table 1, the incubation periods of the sham-operated group and the Chinese herbal medicine were significantly smaller than those of the model group, and the differences were statistically significant. (P <0.05)
2) Water maze space exploration experimental result
TABLE 2 Water maze space exploration experimental results (
Figure BDA0002741874180000063
n=8)
Figure BDA0002741874180000064
Note:P<0.05,△△P<0.01 compared with the sham-operated group,*P<0.05,**P<0.01 comparison with model set
As shown in Table 2, the percentage of time in the second quadrant of the normal group, the sham group, the Chinese group and the Western group was significantly greater than that in the model group, and the differences were statistically significant (P < 0.05).
3.3 measurement results of cerebral blood flow
After the medicine intervention is finished, cerebral blood flow detection is carried out, compared with a sham operation group, the average perfusion amount of the upper half brain area, the lower half brain area and the whole brain area of the model group and the traditional Chinese medicine rat is obviously reduced, and the difference has statistical significance (P is less than 0.05).
Example 5 ischemic white spirit model rat corpus callosum, Hippocampus morphological alterations and Effect of the composition of the invention
1 Material
1.1 Experimental animals
The same as in example 4.
1.2 medicine
The same as in example 4.
2 method
2.1 Molding method
The same as in example 4.
2.2 animal grouping and handling
The same as in example 4.
2.3 methods of administration
The same as in example 4.
2.4 pathological staining and immunohistochemical methods
After anesthesia, the brain tissue is quickly perfused with 0.9% physiological saline at 4 ℃, the brain is taken out after head breaking, the brain tissue is cut off, and embedded and sliced after 4% paraformaldehyde is fixed overnight. 5 rat brain tissue sections were taken from each group for HE staining, myelin staining and immunohistochemistry.
2.4.1HE staining
2.4.3 myelin staining
2.4.3 immunohistochemistry
3 results
3.1 Effect of the Chinese medicinal composition of the present invention on the histological changes of the white matter
3.1.1 callus HE staining
As shown in figure 1, the white matter of the rat in the sham operation group has no obvious abnormality, the white matter fibers are arranged regularly, and the callus vacuoles have smaller area and fewer number; in the model group, corpus callosum white matter fibers are loose and obvious vacuoles are visible; compared with the model group, the Chinese medicinal composition group and the nimodipine group have the advantages that the callus body white matter looseness and vacuole degree are lower, and the Chinese medicinal composition group has a protective effect on white matter damage.
3.1.2 callus myelin staining
As shown in figure 2, the rat corpus callosum LFB of the sham operation group is deeply dyed, white matter fibers are arranged neatly, and no obvious fiber arrangement disorder and no obvious vacuole exist; the model group rat corpus callosum LFB is lighter in staining and has more obvious vacuoles; compared with the model group rats, the Chinese medicinal composition group rats have deeper callus LFB staining and less vacuoles.
TABLE 3 cerebral leukopenia scoring Table
Figure BDA0002741874180000071
Figure BDA0002741874180000081
Note:P<0.05,△△P<0.01 compared to the sham group*P<0.05,**P<0.01 comparison with model set
According to the white matter osteoporosis score standard, the normal score is 0, the nerve fiber disorder score is 1, the obvious vacuole formation score is 2, and the myelinated fiber loss score is 3. The results are shown in table 3, the scores of the normal group and the sham operation group are 0, the score of the model group is significantly higher than that of the sham operation group, the score of the Chinese medicinal composition group is significantly lower than that of the model group, and the difference has statistical significance (P is less than 0.05).
3.1.3 Immunohistorization of the callus region MBP
TABLE 4 mean optical Density of callus MBP immunohistochemistry
Figure BDA0002741874180000082
Note:P<0.05 compared to sham group;*P<0.05 comparison with model set
As shown in Table 4 and FIG. 3, the mean optical density values of MBP immunohistochemistry in the callus region of the sham group were larger than that of the model group, and the difference was statistically significant (P < 0.05). The MBP average optical density value of the traditional Chinese medicine composition group is obviously larger than that of the model group, and the difference has statistical significance (P <0.05)
3.2 Effect of the Chinese medicinal composition of the present invention on Hippocampus histological changes
As shown in FIG. 4, the rat CA1 area in the sham-operated group has no obvious pathological changes, the neurons are arranged in order, the cytoplasm is light red, the nucleus is obvious, and the nucleolus is clear. Loose and disordered cell arrangement, interstitial edema and light staining of the model group; it is seen that the neuron is lost, uneven in size, and the nucleus is cracked; some vessels dilate and perivascular edema appears. The pathological changes of the Chinese medicinal composition group and the nimodipine group hippocampus are lighter than those of the model group.
Example 6 clinical data
The observation of the insomnia and the cognitive function of the patient with ischemic leukoencephalopathy treated by the traditional Chinese medicine composition (sealwort brain-strengthening prescription) of the invention
The collected case data are from aged clinic patients in Guangan department hospital, the clinic time is 12 months in 2018 to 01 months in 2020, and the cases are finally included in 77 patients with ischemic encephaloleukosis. All patients are treated by decoction of the traditional Chinese medicine composition orally. The basic method comprises the following steps: 8-30 parts of wine sealwort, 10-50 parts of kudzu root, 10-30 parts of tuckahoe, 6-15 parts of prepared polygala root and 0.2-1.0 part of artificial bezoar. The treatment is continued for 12 weeks according to the specific symptoms of the patients. Safety checks and scale tests (PSQI scale, SPIEGEL scale, chinese medical symptom score, MoCA scale, MMSE scale) were performed at the time of group entry and after 12 weeks of treatment. The quantitative table test (PSQI scale, symptom score table of chinese medicine) was performed 4 weeks after treatment and 8 weeks after treatment.
In 77 cases, the mean age was 63.43 ± 8.079 years. Wherein the proportion of people with age not less than 61 and not more than 70 years old is 50.6 percent at most. 27 men and 50 women. Most subjects are accompanied by basic diseases, and the basic diseases are mainly cardiovascular and cerebrovascular diseases. The diseases of the first three patients in the rows are respectively: hyperlipidemia (66), hypertension (48), lacunar infarction (38).
The clinical curative effect is judged according to the PSQI scale, 3 cases are clinically cured, 14 cases are obviously effective, 53 cases are effective, 7 cases are ineffective, and the total effective rate reaches 90.9%. In the aspect of improving the Pittsburgh sleep quality index scale (PSQI), the statistical result shows that all scores and the total score P value of the PSQI scale of the subject of the traditional Chinese medicine composition are less than 0.05, the difference has statistical significance, and the sleep quality, the sleep time, the sleep efficiency, the sleep disorder and the daytime dysfunction of the subject after treatment are all improved compared with those before treatment. And comparing each score in pairs at different treatment time periods, adjusting the alpha level by adopting a Bonferroni method, finding that the P value of each score is more than 0.05 after adjustment when each score is compared between the 8 th week of treatment and the 4 th week of treatment, and the difference has no statistical significance, which shows that the sleep condition of the subject is not greatly influenced when the score is compared between the 8 th week of treatment and the 4 th week of treatment, and the sleep condition of the subject can be improved when the score is compared between the 12 th week of treatment and the 8 th week of treatment. In the aspect of improving the clinical observation questionnaire (SPIEGEL) of insomnia, compared with the treatment week 12 before treatment, the time to fall asleep, the total sleep time, the number of awakenings at night, the sleep depth, the nighttime dreaming condition and the postwake feeling P value of the subject are all less than 0.05, and the difference has statistical significance, which indicates that the time to fall asleep, the total sleep time, the number of awakenings at night, the sleep depth, the nighttime dreaming condition and the postwake feeling of the subject at the treatment week 12 are all improved compared with those before treatment.
Comparing the total score of the MoCA scale of the subject before treatment with the total score of the MoCA scale before treatment at 12 weeks, the P value is less than 0.05, the difference has statistical significance, and the result shows that the total score of the MoCA scale is increased at 12 weeks compared with the total score of the MoCA scale before treatment. Compared with the scores of the MoCA scale at the 12 th week of treatment before treatment, the P values are less than 0.05 except for orientation, and the difference has statistical significance, which indicates that the scores of visual space and executive function, naming, attention, language, abstraction and delayed recall function of the subject at the 12 th week of treatment are increased compared with the scores before treatment. Comparing the total score of the MMSE scale of the subjects before and at the 12 th week of treatment, the P value is less than 0.05, the difference has statistical significance, and the total score of the MMSE scale of the subjects at the 12 th week of treatment is increased compared with the total score before the treatment. Compared with the subjects before and after treatment in the aspects of attention calculation, memory ability, repetition and structural function, the P value is less than 0.05, the difference has statistical significance, and the results show that the scores of the subjects in the 12 th week of treatment in the aspects of attention calculation, memory ability, repetition and structural function are all increased compared with the scores before treatment. The traditional Chinese medicine composition can effectively improve the sleep condition, cognitive function and traditional Chinese medicine symptoms of patients with ischemic leukoencephalopathy.
Typical cases and efficacy:
(1) obvious vertigo
Initial diagnosis: zhao xx, female, age 64, in southern area of Guanan Hospital, college of traditional Chinese medicine. The main complaints are: vertigo with fatigue for more than 2 months. The following symptoms are marked: amnesia, dizziness, low mood, lack of interest, vexation, anxiety, fear, aversion to cold, and aversion to heat. Headache, tinnitus, blurred vision, anorexia, abdominal distention after eating, acid regurgitation, insomnia, dreaminess, dry stool, 1 time/1-2 days, and urination. Pale with white coating and wiry, thready and rapid pulse. And (3) Western diagnosis: 1. leukoencephalopathy 2, anxiety 3, chronic gastritis. The traditional Chinese medicine diagnoses the stagnation syndrome of liver-qi stagnation and spleen deficiency and fire excess from yin deficiency. Therapeutic method, soothing liver and relieving depression, invigorating qi and spleen, and nourishing heart and kidney.
The prescription is as follows: 10g of wine-processed rhizoma polygonati, 30g of kudzu root, 20g of poria cocos, 10g of prepared polygala tenuifolia, 0.25g of artificial bezoar (separately brewed) and 10g of gastrodia elata.
Seven doses are decocted with water for oral administration, one dose is taken every day, and the dose is divided into morning and evening.
And B, diagnosis: patients still lack interest in the relief of dizziness, are afraid of cold and heat, have relieved headache and are not fragrant to eat, can sleep for 5 hours at night, and are convenient to adjust. The tongue is pale red, the coating is white, and the pulse is wiry, thready and rapid. The prescription is that the upper part is unchanged, seven doses are taken, the decoction is decocted with water, one dose is taken every day, and the decoction is taken warm in the morning and at night. According to the principle, the symptoms of the patient are relieved earlier, so the patient keeps the original prescription unchanged and then observes.
Three diagnoses: patients complain of no obvious dizziness, good mood, further relief of anxiety, aversion to cold, reduction of blurred vision, increase of accommodation, abdominal distension, sleep for 7-8h at night, reduction of dream and convenient adjustment. The tongue is pale red, the coating is thin and white, and the pulse is wiry and thready. The prescription is added above, magnolia officinalis 6 is added, seven doses are taken, and the decoction is decocted with water, one dose is taken every day, and the decoction is taken warm in the morning and evening. According to the recipe, cortex Magnoliae officinalis, radix aucklandiae and fructus Amomi are added to promote the circulation of qi and relieve abdominal distention.
(2) Obvious insomnia
Initial diagnosis: patient, female, 65 years old. The main complaints are: difficulty in falling asleep, light sleep and easy waking for 6 years. The current medical history: the Chinese date seed nerve soothing capsule, the nerve soothing and brain tonifying liquid and the acupuncture point acupuncture therapy are sequentially taken, and the symptoms are not obviously relieved. The symptoms of difficult falling asleep, light sleep and easy waking up, difficult sleeping after waking up, dreaminess, early waking up, early morning head coma and discomfort, daytime mental lassitude, dizziness and hypodynamia, palpitation, chest distress and shortness of breath, amnesia, inattention, dry mouth, eye dryness, plain aversion to heat, low mood, soreness and weakness of waist and knees, anorexia, small stool for 3 times or 4 times at night and normal stool. A dark red tongue with little coating and dry texture and a wiry and thready pulse. Biochemical examination of blood Low Density lipoprotein Cholesterol (LDL-C): 2.67mmol/L, Homocysteine (HCY): 16.5 umol/L. Head magnetic resonance display: ischemic leukoencephalopathy. And (3) Western diagnosis: insomnia, ischemic encephalopathy, hyperlipidemia, and hyperhomocysteinemia. Traditional Chinese medicine diagnosis: insomnia (liver and kidney yin deficiency syndrome). Therapeutic principle: tonify kidney, replenish essence, calm brain. Dialectical administration:
the prescription is as follows: 15g of wine-processed rhizoma polygonati, 15g of kudzu root, 15g of poria cocos, 9g of prepared polygala tenuifolia, 0.25g of artificial bezoar (separately brewed), 15g of salvia miltiorrhiza and 50g of spina date seed.
After the subsequent treatment, the prescription is slightly modified along with the change of the disease condition, after 6 months of treatment, the sleep of the patient is improved earlier, the sleep recovery time after waking up at night is shortened earlier, the sleep time can reach 5-6 h every night, and the rest symptoms are relieved earlier.
(3) Obvious amnesia
Initial diagnosis: hongxx, female, 66 years old, complaint memory decline for more than 10 years, aggravated for 2 days, unstable blood pressure (190/80 mmHg today). Hypomnesis, insomnia, dreaminess, sweating on exertion, frequent nocturia, numb soles, red tongue with little coating, dry tongue and thready and rapid pulse. MRI: brain atrophy, leukoencephalopathy, lacunar infarction. The existing method has hypertension, diabetes, and hyperlipidemia for more than ten years. And (3) diagnosis: 1. type 2.2 diabetes of white brain disease, 3 grade 3 hypertension, 4 grade hyperlipidemia, traditional Chinese medicine diagnosis: treatment for liver and kidney deficiency and qi and yin deficiency: tonify liver and kidney, nourish yin to reduce pathogenic fire.
The prescription is as follows: 20g of wine-processed rhizoma polygonati, 30g of kudzu root, 30g of poria cocos, 10g of prepared polygala tenuifolia, 0.5g of artificial bezoar (fen chong), 20g of salvia miltiorrhiza, 15g of spina date seed and 10g of fructus alpiniae oxyphyllae.
Seven doses are decocted with water for oral administration, one dose is taken every day, and the dose is divided into morning and evening.
And B, diagnosis: patients complain of sleep improvement and have strengthened memory, and can remember steamed stuffed buns eaten at breakfast when seeing a doctor. Blood pressure 144/76 mmHg. Effective above, take 14 doses sequentially.
After the patient is treated for three months, the blood pressure, the blood fat and the blood sugar are basically stable and normal, and the insomnia and the amnesia are obviously improved.
(4) Obvious depression
Initial diagnosis: korea xx, male, 68 years old, saw a doctor in Guangan Hospital, Chinese academy of traditional Chinese medicine. The main complaints are: dizziness attacks repeatedly for more than 20 years. The following symptoms are marked: amnesia, low mood, fear, photophobia. Debilitation, excessive sweat, stiff body, frequent trembling, anorexia, insomnia, occasional incontinence of the urine and stool, pale tongue with white and thick coating, thin and string left pulse, weak right pulse. Head MRI: white brain disease. The Montgomery depression rating Scale (MADRS) was measured: 24 points, hamilton anxiety scale (HAMA): 16 minutes. Currently used sertraline 50mg po qd, lorazepam 0.5mg po tid, zopiclone 7.5mg po qn. And (3) Western diagnosis: 1. depression 2, anxiety 3, and white spirit disease, depression syndrome of liver-qi stagnation and spleen deficiency, and deficiency of heart-kidney yang. Therapeutic method, soothing liver, strengthening spleen, warming and invigorating spleen and kidney, nourishing heart and tranquilizing mind. Modified prescription for relieving mental stress.
The prescription is as follows: 30g of kudzuvine root, 15g of rhizoma polygonati, 10g of tuckahoe, 12g of prepared polygala root, 0.25g of artificial bezoar (fen chong), 15g of morinda officinalis, 10g of bupleurum and 10g of red paeony root.
Seven doses, and granules, one dose per day, taken in the morning and evening. The western medicines are as before.
And B, diagnosis: the patients in the clinic feel that the chest is wide, the interest is gradually increased, the sweating is slightly reduced and still sweats, the body is trembled and controlled, the patients can sleep for 4 to 5 hours/night after the patients feel out of the doctor and complain about the diseases, the patients have occasional incontinence on the urine and the urine, the tongue is pale, the coating is white and thick, the pulse is thin and string on the left side, and the pulse is slow on the right side. The Montgomery depression rating Scale (MADRS) was retested: score 19, hamilton anxiety scale (HAMA): and 12 minutes. Prescription: above the mixture, 30g of blighted wheat was added. Seven doses, and granules, one dose per day, taken in the morning and evening.
Three diagnoses: the patient can complain of the emotional condition after the re-diagnosis, no palpitation or chest distress occurs, no obvious touch feeling can be resisted when the patient communicates with the patient, the sweating is obviously reduced, the trembling of the body can be controlled, the patient can take the sleep, the patient can defecate, the frequent micturition is frequent, and the color is white. A pale and surging tongue with thin and white coating and a wiry pulse left and a gentle pulse right. Retest montgomery depression rating scale (MADRS): 13 points, hamilton anxiety scale (HAMA): 9 minutes. Prescription: on the upper part, 14 doses of granules are taken in the morning and at night. The western medicines are as before. After the treatment, the patient is returned to the clinic, and then the normal living condition is basically restored by the method of warming and invigorating spleen and kidney, soothing liver and strengthening spleen, and nourishing heart and tranquilizing mind.
It should be understood that the above-mentioned embodiments of the present invention are only examples for clearly illustrating the present invention, and are not intended to limit the embodiments of the present invention, and it will be obvious to those skilled in the art that other variations or modifications may be made on the basis of the above description, and all embodiments may not be exhaustive, and all obvious variations or modifications may be included within the scope of the present invention.

Claims (7)

1. A traditional Chinese medicine composition for treating leukoencephalopathy is characterized by being prepared from the following raw material medicines in parts by weight: 8-30 parts of wine sealwort, 10-50 parts of kudzu root, 10-30 parts of tuckahoe, 6-15 parts of prepared polygala root and 0.2-1.0 part of artificial bezoar.
2. The traditional Chinese medicine composition of claim 1, wherein the bulk drug further comprises: 10-30 parts of gastrodia elata.
3. The traditional Chinese medicine composition of claim 1, wherein the bulk drug further comprises: 10-30 parts of salvia miltiorrhiza and 10-60 parts of spina date seed.
4. The traditional Chinese medicine composition of claim 1, wherein the bulk drug further comprises: 6-15 parts of fructus alpiniae oxyphyllae.
5. The traditional Chinese medicine composition of claim 1, wherein the bulk drug further comprises: 6-15 parts of bupleurum, 6-20 parts of red peony root and 6-20 parts of morinda officinalis.
6. The Chinese medicinal composition according to any one of claims 1 to 5, which is prepared into decoction, granules, pills, capsules, tablets, powder or oral liquid.
7. Use of the Chinese medicinal composition of any one of claims 1-6 in the preparation of a medicament for the treatment of leukoencephalopathy.
CN202011153269.5A 2020-10-26 2020-10-26 Traditional Chinese medicine composition for treating leukoencephalopathy and application thereof Active CN112402554B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202011153269.5A CN112402554B (en) 2020-10-26 2020-10-26 Traditional Chinese medicine composition for treating leukoencephalopathy and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202011153269.5A CN112402554B (en) 2020-10-26 2020-10-26 Traditional Chinese medicine composition for treating leukoencephalopathy and application thereof

Publications (2)

Publication Number Publication Date
CN112402554A true CN112402554A (en) 2021-02-26
CN112402554B CN112402554B (en) 2022-03-01

Family

ID=74840211

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202011153269.5A Active CN112402554B (en) 2020-10-26 2020-10-26 Traditional Chinese medicine composition for treating leukoencephalopathy and application thereof

Country Status (1)

Country Link
CN (1) CN112402554B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116270880A (en) * 2023-04-23 2023-06-23 中国中医科学院广安门医院 Traditional Chinese medicine composition for improving brain emotion network function and white matter structural integrity and treating insomnia and anxiety disorder, preparation and application thereof

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1552415A (en) * 2003-06-03 2004-12-08 天津天士力制药股份有限公司 Medicine for treating dementia and preparing method thereof
CN102861290A (en) * 2012-09-10 2013-01-09 冯伟敏 Chinese medicinal preparation having brain-invigorating and intelligent-benefiting functions
JP2017043616A (en) * 2015-08-27 2017-03-02 学校法人慶應義塾 14-3-3 Protein activity regulator
CN107982442A (en) * 2017-12-15 2018-05-04 兖矿集团有限公司总医院 A kind of kidney tonifying resolving sputum, the medicament composing prescription of opening the orifice and activating blood circulation
CN110201118A (en) * 2019-06-10 2019-09-06 吉林修正药业新药开发有限公司 A kind of Chinese medicine composition treats or prevents the application in vascular senile dementia drug in preparation
CN110215508A (en) * 2019-07-18 2019-09-10 无锡市中医医院 A kind of preparation process of Shu Yu herbal mixture and its manufactured dosage form and each dosage form
CN111419861A (en) * 2020-04-29 2020-07-17 广东省中医院(广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院) Chinese medicinal effective component compound preparation for treating vascular dementia and application thereof
US20200241012A1 (en) * 2014-09-10 2020-07-30 AbbVie Deutschland GmbH & Co. KG RGMa Fragment Based Diagnostic Assay
CN111743934A (en) * 2020-06-23 2020-10-09 江苏省中医院 Traditional Chinese medicine composition for regulating intestinal flora and application thereof

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1552415A (en) * 2003-06-03 2004-12-08 天津天士力制药股份有限公司 Medicine for treating dementia and preparing method thereof
CN102861290A (en) * 2012-09-10 2013-01-09 冯伟敏 Chinese medicinal preparation having brain-invigorating and intelligent-benefiting functions
US20200241012A1 (en) * 2014-09-10 2020-07-30 AbbVie Deutschland GmbH & Co. KG RGMa Fragment Based Diagnostic Assay
JP2017043616A (en) * 2015-08-27 2017-03-02 学校法人慶應義塾 14-3-3 Protein activity regulator
CN107982442A (en) * 2017-12-15 2018-05-04 兖矿集团有限公司总医院 A kind of kidney tonifying resolving sputum, the medicament composing prescription of opening the orifice and activating blood circulation
CN110201118A (en) * 2019-06-10 2019-09-06 吉林修正药业新药开发有限公司 A kind of Chinese medicine composition treats or prevents the application in vascular senile dementia drug in preparation
CN110215508A (en) * 2019-07-18 2019-09-10 无锡市中医医院 A kind of preparation process of Shu Yu herbal mixture and its manufactured dosage form and each dosage form
CN111419861A (en) * 2020-04-29 2020-07-17 广东省中医院(广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院) Chinese medicinal effective component compound preparation for treating vascular dementia and application thereof
CN111743934A (en) * 2020-06-23 2020-10-09 江苏省中医院 Traditional Chinese medicine composition for regulating intestinal flora and application thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
韩露露,黄世敬,潘菊华: "从"脑神学说"论应用脑引经药治疗不寐", 《中西医结合心脑血管病杂志》 *
马丽等: "开心解郁方在血管性抑郁症治疗中的应用", 《辽宁中医杂志》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116270880A (en) * 2023-04-23 2023-06-23 中国中医科学院广安门医院 Traditional Chinese medicine composition for improving brain emotion network function and white matter structural integrity and treating insomnia and anxiety disorder, preparation and application thereof
CN116270880B (en) * 2023-04-23 2024-01-26 中国中医科学院广安门医院 Traditional Chinese medicine composition for improving brain emotion network function and white matter structural integrity and treating insomnia and anxiety disorder, preparation and application thereof

Also Published As

Publication number Publication date
CN112402554B (en) 2022-03-01

Similar Documents

Publication Publication Date Title
CN101444611B (en) Traditional Chinese medicine composition for treating lumbocrural pain and lumbar intervertebral disc protrusion and preparation method thereof
CN112826900B (en) Traditional Chinese medicine composition for treating seborrheic alopecia and pharmaceutical preparation thereof
CN112402554B (en) Traditional Chinese medicine composition for treating leukoencephalopathy and application thereof
CN104147518A (en) Traditional Chinese medicinal capsule for treating depression and preparation method thereof
CN104623433A (en) Traditional Chinese medicine for preventing postanesthesia shivering and preparation method of traditional Chinese medicine
CN106377635A (en) Traditional Chinese medicine formula for reducing white hair and gray hair
CN110368470A (en) Composition and its application for preventing and treating metabolic syndrome
CN109646526A (en) A kind of Chinese medicine composition and preparation method thereof for treating depression
CN105343675A (en) Traditional Chinese medicine preparation for treating adiposis and preparation method thereof
CN102552677B (en) Coptis chinensis and radix rehmanniae Anxiao capsule and preparation method thereof
CN102716260B (en) Medicine for fast improving sperm quality and sexual function
CN100450519C (en) Chinese medicine preparation for changing diabetes II insulin resistance and sugar, fat metabolic disorder
CN104906394A (en) Traditional Chinese medicine for treating liver and kidney yin deficiency and qi and blood deficiency type hypertension
CN104689151A (en) Traditional Chinese medicine composition for treating diabetes and use of composition
CN101199761B (en) Drug for treating arteriosclerosis
CN104352973A (en) Chinese patent medicine for postpartum depression
CN116549590B (en) Traditional Chinese medicine composition for treating chronic insomnia and application thereof
CN109125693A (en) For improving the Chinese herbal medicine of myocardial blood supply, drug paste and the preparation method of drug paste
CN103223107A (en) Traditional Chinese medicine used for adjusting blood fat and blood pressure, and preparation technology thereof
CN116139236B (en) Traditional Chinese medicine composition for treating liver depression type insomnia and application thereof
CN106389577A (en) Traditional Chinese medicine composition capable of blackening and brightening hair
CN113413445B (en) Composition and preparation method and application thereof
CN106606744A (en) Combination medicament for treating type 2 diabetes mellitus
CN1289609A (en) Chinese patent medicine (Tangweiping) for treating eyeground affection of diabetes
CN104645244A (en) Traditional Chinese medicine composition for treating atherosclerosis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant